There continues to be a great deal of buzz around real world data. For biopharmaceutical companies raised on conventional market research, the ability to now access data pulled directly from insurance claims and electronic health records (EHR) translates to a major upgrade in analytical muscle. At least, that’s the theory.
In practice, real world data projects are extremely challenging. The data is expensive to buy, time-consuming to process, and requires a great deal of analytical and therapeutic expertise to turn into reliable, meaningful, actionable insights. But done right, real world data has the potential to boost brand performance, fine-tune commercial strategy, tease out subtle market nuances, and unlock hidden opportunities.
In a recent interview, DRG’s Mladen Tomich discusses the challenges of accessing and analyzing real world data for pharma companies.
Contact us to learn how DRG's therapeutic experts can help you transform real world data into actionable insights.